Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Inhibrx Biosciences, Inc. from 30 Jun 2023 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Inhibrx Biosciences, Inc. quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 30 Jun 2023 to 30 Sep 2025.
  • Inhibrx Biosciences, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Sep 2025 was $35,256,000, a 20% increase year-over-year.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)

Inhibrx Biosciences, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $35,256,000 +$8,608,000 +20% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $28,652,000 -$1,886,665,000 -102% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $43,311,000 +$35,399,000 +45% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q3 2024 $43,864,000 +$7,923,000 +15% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $1,858,013,000 +$1,905,060,000 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $78,710,000 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q3 2023 $51,787,000 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $47,047,000 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.